NovoCure (NVCR) Cash from Operations Growth (1y) (2015 - 2026)
NovoCure (NVCR) Cash from Operations Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | 21.54% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 13.50% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 14.62% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 124.64% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | -11.16% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 78.72% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -0.23% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | -12.60% |
| 10 | NovoCure | 2.03 Bn | 1.59 Bn | 142.48 Mn | 151.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 151.03% |
| Mar 31, 2026 | 62.10% |
| Dec 31, 2025 | -421.70% |
| Sep 30, 2025 | 98.28% |
| Jun 30, 2025 | -826.51% |
| Mar 31, 2025 | -12.96% |
| Dec 31, 2024 | 76.29% |
| Sep 30, 2024 | 153.72% |
| Jun 30, 2024 | 92.44% |
| Mar 31, 2024 | -88.76% |
| Dec 31, 2023 | -292.72% |
| Sep 30, 2023 | -186.15% |
| Jun 30, 2023 | -244.25% |
| Mar 31, 2023 | -353.68% |
| Dec 31, 2022 | -125.74% |
| Sep 30, 2022 | -8.11% |
| Jun 30, 2022 | -39.78% |
| Mar 31, 2022 | -120.74% |
| Dec 31, 2021 | -73.07% |
| Sep 30, 2021 | -21.21% |